Gregg Gilbert
Stock Analyst at Truist Securities
(3.68)
# 890
Out of 4,415 analysts
42
Total ratings
55.56%
Success rate
4.94%
Average return
Main Sectors:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $11.77 | +44.44% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $37.51 | -1.36% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $43.70 | +92.22% | 4 | Sep 15, 2023 | |
| LLY Eli Lilly | Maintains: Buy | $430 → $525 | $755.91 | -30.55% | 6 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $13.22 | -1.66% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $14.19 | - | 8 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | n/a | $128.26 | - | 2 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | n/a | $8.60 | - | 1 | Feb 2, 2021 | |
| CHRS Coherus BioSciences | Initiates: Buy | n/a | $2.17 | - | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | n/a | $0.18 | - | 1 | Jan 24, 2020 | |
| PRGO Perrigo Company | Downgrades: Hold | n/a | $33.06 | - | 2 | Aug 10, 2018 | |
| ZTS Zoetis | Maintains: Hold | n/a | $167.23 | - | 4 | Feb 16, 2018 | |
| TEVA Teva Pharmaceutical | Maintains: Hold | n/a | $14.08 | - | 2 | Feb 9, 2018 | |
| LGND Ligand Pharmaceuticals | Downgrades: Sell | n/a | $72.32 | - | 3 | Nov 20, 2017 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | n/a | $109.29 | - | 2 | Aug 9, 2017 | |
| ABBV AbbVie | Maintains: Hold | n/a | $160.81 | - | 1 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $11.77
Upside: +44.44%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $37.51
Upside: -1.36%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $43.70
Upside: +92.22%
Eli Lilly
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $755.91
Upside: -30.55%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $13.22
Upside: -1.66%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $14.19
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: n/a
Current: $128.26
Upside: -
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: n/a
Current: $8.60
Upside: -
Coherus BioSciences
Apr 17, 2020
Initiates: Buy
Price Target: n/a
Current: $2.17
Upside: -
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: n/a
Current: $0.18
Upside: -
Perrigo Company
Aug 10, 2018
Downgrades: Hold
Price Target: n/a
Current: $33.06
Upside: -
Zoetis
Feb 16, 2018
Maintains: Hold
Price Target: n/a
Current: $167.23
Upside: -
Teva Pharmaceutical
Feb 9, 2018
Maintains: Hold
Price Target: n/a
Current: $14.08
Upside: -
Ligand Pharmaceuticals
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $72.32
Upside: -
Jazz Pharmaceuticals
Aug 9, 2017
Maintains: Buy
Price Target: n/a
Current: $109.29
Upside: -
AbbVie
Jul 17, 2017
Maintains: Hold
Price Target: n/a
Current: $160.81
Upside: -